profit from every $100 of sales.
$0$100
Liquidia
$47.87+7.82% today
+83.5% in 1 year
1-year low $25.911-year high $91.03
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Liquidia sold, what it kept, and what it did with the cash.
Sales went from $15.9 million in 2022 to $158 million in 2025, with -$68.9 million of profit last year.
SalesProfit
Liquidia vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Liquidia | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Liquidia's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 16 | 17 | 14 | 158 | |
| 13 | 15 | 8 | 145 | |
| -39 | -73 | -121 | -51 | |
| -35 | -70 | -111 | -43 | |
| -41 | -79 | -128 | -69 | |
| -0.67 | -1.21 | -1.66 | -0.80 | |
| 82.1% | 83.5% | 58.0% | 91.6% | |
| -243.3% | -419.6% | -866.6% | -32.5% | |
| -257.4% | -448.9% | -916.6% | -43.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 129 | 118 | 230 | 328 |
| Cash | 93 | 84 | 176 | 191 |
| Total debt | 24 | 50 | 120 | 198 |
| Total liabilities | 39 | 71 | 151 | 283 |
| 90 | 47 | 79 | 45 | |
| 61 | 65 | 79 | 86 | |
| -26.6% | -58.9% | -45.0% | -14.6% | |
| -45.4% | -166.0% | -161.6% | -154.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -42 | -93 | -36 | |
| 1 | 11 | 8 | 6 | |
| -29 | -53 | -102 | -42 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 10 | 19 | 29 |
Valuation
- –
- 19.9×
- –
- 49.4×
- 27.1×
- –
- –
- -1.0%
- -1.6%
- 0.0%
Profitability
- 91.6%
- -32.5%
- -43.5%
- 18.1%
- 12.8%
- -50.6%
- 46.8%
- 5.6%
- 18.1%
- 15.5%
Growth
- +115.0%
- –
- +59.3%
- –
- +14.7%
Financial health
- –
- 1.70
- 46.0%
- 1.8×
- 2.22
- 2.03
- 0.72
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 948
Bottom 9%of 871
Top 5%of 868
Bottom 35%of 985
What analysts expect
- Average price target
- $55.00
- Range
- $55.00 – $55.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.52 | 0.34 | +52.9% |
| Mar 5, 2026 | 0.15 | 0.08 | +87.5% |
| Nov 3, 2025 | -0.04 | -0.45 | +91.1% |
| Aug 12, 2025 | -0.49 | -0.43 | −14.0% |
| May 8, 2025 | -0.45 | -0.42 | −7.1% |
| Mar 19, 2025 | -0.46 | -0.38 | −21.1% |
| Nov 13, 2024 | -0.37 | -0.37 | +0.0% |
| Aug 7, 2024 | -0.37 | -0.35 | −5.7% |
News
How Much Downside Is Left In Liquidia Stock?Yahoo Finance · Oct 15, 2026Liquidia Corporation Q2 2026 Earnings Call SummaryYahoo Finance · Aug 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
24No pass
Philip Fisher
40No pass
Peter Lynch
24No pass
Joel Greenblatt
14No pass
Charlie Munger
27No pass
Terry Smith
30No pass
Questions about Liquidia
Is Liquidia a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Liquidia AI analysis
What does Liquidia do?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. It is in Biotechnology, based in Morrisville, NC, United States, with 216 employees.
Does Liquidia pay a dividend?
No. Liquidia does not pay a dividend at the moment.
Is Liquidia stock halal?
Yes. Liquidia passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Liquidia stock done over the past year?
Up 83.5% over the past twelve months, to $47.87. It traded between $25.91 and $91.03 and is 47.4% below its high.
Who are Liquidia's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Liquidia's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.